GlassScriptPhysician profile
Corrie Alexis Baker
NPI 1376237941
$3,430.81
in general payments reported to CMS, 2019-2025
21 companies · $2,041 in 2025
The $2,041 reported for 2025 was more than what 93% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $344 · 2024: $1,045 · 2025: $2,041.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,395 · Education: $35.74.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,395.07 |
| Education | $35.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $535.65 | 2024-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $401.83 | 2023-2025 | Xifaxan, Trulance |
| Madrigal Pharmaceuticals | $362.98 | 2024-2025 | Rezdiffra, Resmetirom |
| Boston Scientific Corporation | $330.35 | 2024-2025 | Exalt Model D |
| Takeda Pharmaceuticals U.S.A., INC. | $269.92 | 2023-2025 | Entyvio, Gattex |
| Mallinckrodt Hospital Products INC. | $220.26 | 2025 | Terlivaz |
| Medtronic, INC. | $163.25 | 2025 | Gi Genius |
| Lilly USA, LLC | $143.18 | 2023-2024 | Omvoh, Zepbound |
| Phathom Pharmaceuticals, INC. | $122.67 | 2024 | Voquezna |
| Gilead Sciences, INC. | $118.84 | 2025 | Livdelzi |
| Ardelyx, INC. | $115.62 | 2025 | Ibsrela |
| Celltrion USA INC. | $112.10 | 2023-2025 | Vegzelma, Zymfentra, Yuflyma |
| Fujifilm Healthcare Americas Corporation | $111.97 | 2023 | Utaswako Afp-L3 |
| Sandoz INC. | $108.03 | 2024-2025 | Hyrimoz |
| Regeneron Healthcare Solutions, INC. | $107.72 | 2025 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $90.51 | 2025 | Krystexxa |
| Daiichi Sankyo INC. | $26.32 | 2025 | Injectafer |
| Merck Sharp & Dohme LLC | $26.03 | 2024 | Dificid |
| Ipsen Biopharmaceuticals, INC | $24.04 | 2024 | Iqirvo |
| Qol Medical, LLC | $21.32 | 2023 | Sucraid |
| Organon LLC | $18.22 | 2023 | Hadlima, Renflexis |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Corrie Baker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.